Evidence mapPaperPMID 39254049Full record

ArticlemSphere2024

Testosterone treatment impacts the intestinal microbiome of transgender individuals.

Rebecca M Harris, Fernanda Pace, Thomas M Kuntz, Xochitl C Morgan, Phoebe Hyland, Kiana Summers, Em McDermott, Kai Blumen, Paula I Watnick

Abstract read
In one paragraph

Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rebecca M HarrisDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-2170-9487
Fernanda PaceDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Thomas M KuntzHarvard Chan Microbiome Analysis Core, Department of Biostatistics, Harvard Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-0823-0340
Xochitl C MorganHarvard Chan Microbiome Analysis Core, Department of Biostatistics, Harvard Chan School of Public Health, Boston, Massachusetts, USA.
Phoebe HylandDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Kiana SummersDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Em McDermottDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Kai BlumenDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Paula I WatnickDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-9173-8662

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medical modulation of sex hormone levels is a cornerstone of treatment for many conditions that impact well-being, including cancer, fertility/infertility, gender dysphoria, and chronic metabolic diseases such as diabetes and obesity. The microbial residents of the intestine, known as the microbiota, interact with sex hormones in the intestine, and there is correlative evidence that this interaction is bidirectional. Based on these published findings, we hypothesized that transgender individuals receiving exogenous testosterone as part of their gender-affirming medical treatment might undergo changes in their intestinal microbiome. To test this, we collected 26 stool samples from nine individuals before and up to 8 months after initiation of treatment with exogenous testosterone and subjected these samples to metagenomic analysis. While no species were significantly associated with the duration of testosterone therapy, pathways that generate glutamate increased in abundance, while those that consume glutamate decreased. Glutamate is a precursor of arginine, and testosterone is known to increase levels of arginine and its metabolites in the plasma. We hypothesize that testosterone increases the uptake of glutamate by enterocytes, thus decreasing access of the microbiota to this amino acid. While this pilot study establishes the impact of testosterone therapy on the intestinal microbiome, a more comprehensive study is necessary to establish the impact of testosterone-driven metagenomic shifts on the stool metatranscriptome, the stool metabolome, and the plasma metabolome.IMPORTANCEThe human intestine is inhabited by a large community of microbes known as the microbiome. Members of the microbiome consume the diet along with their human host. Thus, the metabolomes of the host and microbe are intricately linked. Testosterone alters the plasma metabolome. In particular, plasma levels of arginine and its metabolites and testosterone are positively correlated. To investigate the impact of exogenous testosterone on the microbiome, we analyzed the stool metagenomes of transgender individuals before and after the initiation of testosterone treatment. In this pilot project, we found a modest impact on the microbiome community structure but an increase in the abundance of metabolic pathways that generate glutamate and spare glutamate consumption. We propose that the host uses glutamate to generate arginine, decreasing the amount available for the microbiome.

Indexed as

FecesGastrointestinal MicrobiomeTestosteroneTransgender PersonsAdultBacteriaFemaleGlutamic AcidHumansMaleMetagenomicsMiddle AgedPilot ProjectsGlutamic AcidTestosteronearginine metabolismgut microbiomehuman microbiomemetagenomicstestosteronetransgender

Identifiers

PMID39254049
PMCPMC11520287

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.